A PHASE I/II, OPEN LABEL STUDY OF SPC2996 IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED FOLLICULAR OR LYMPHOPLASMACYTIC NON-HODGKIN'S LYMPHOMA

Trial Profile

A PHASE I/II, OPEN LABEL STUDY OF SPC2996 IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED FOLLICULAR OR LYMPHOPLASMACYTIC NON-HODGKIN'S LYMPHOMA

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 24 May 2012

At a glance

  • Drugs Rituximab; SPC 2996
  • Indications Follicular lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
  • Sponsors Santaris Pharma
  • Most Recent Events

    • 24 May 2012 Actual end date (7 Nov 2008) added as reported by European Clinical Trials Database record.
    • 24 May 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
    • 12 Jul 2011 This study has been completed in the Czech Republic (7 Nov 2008) and discontinued in Hungary (7 Nov 2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top